MARKSANS PHARMA
|
The Current P/E Ratio of MARKSANS PHARMA is 26.89.
| Share Price | ₹309.3 | Oct 09,2026 |
| Market Cap | ₹14,015.2 Cr | |
| Earnings-TTM | ₹521.3 Cr | TTM-Consolidated Results |
| Price/Earnings | 26.89x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of MARKSANS PHARMA
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹14,015.2 Cr] as on Oct 09,2026
(/) Earnings [ ₹521.3 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 26.89x ]
Thus, for MARKSANS PHARMA , the investors are currently willing to pay 26.89 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of MARKSANS PHARMA !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of MARKSANS PHARMA over the last five years.
Historical PE (Price/Earnings) ratio chart of MARKSANS PHARMA
PE Ratio Performance Analysis for MARKSANS PHARMA
- MARKSANS PHARMA 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 17.50x.
- MARKSANS PHARMA 's operated at median p/e ratio of 17.04x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, MARKSANS PHARMA 's p/e ratio peaked in Mar2025 at 26.48x.
- MARKSANS PHARMA 's p/e ratio hit its five-year low in Mar2022 of 10.1x.
How does MARKSANS PHARMA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| MARKSANS PHARMA | 521.27 | 26.89 | 14,015.2 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 12,172.70 | 34.63 | 421,539.0 |
| DIVIS LABORATORIES LTD | 2,925.00 | 84.64 | 247,576.0 |
| TORRENT PHARMACEUTICALS LTD | 2,156.00 | 82.21 | 177,251.0 |
| CIPLA LTD | 3,364.84 | 31.29 | 105,290.0 |
| DR REDDYS LABORATORIES LTD | 3,169.30 | 31.47 | 99,752.6 |
| MANKIND PHARMA LTD | 2,055.11 | 47.61 | 97,850.4 |
| LUPIN LTD | 5,551.01 | 16.15 | 89,628.8 |
| ZYDUS LIFESCIENCES LTD | 4,492.20 | 24.76 | 111,232.0 |
| AUROBINDO PHARMA LTD | 3,712.74 | 26.13 | 97,014.5 |
| LAURUS LABS LTD | 1,090.76 | 100.66 | 109,797.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs MARKSANS PHARMA 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 16.15x |
| Max industry PE | 100.66x |
| Median industry PE | 31.47x |
| Average industry PE | 46.04x |
You may also like the below Video Courses